News

Currently, BUNAVAIL is under review at the US Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of 07 June 2014. If BUNAVAIL

Proceeds from the contract will be used to develop an inhaled PDGF receptor kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The VITA contract will fund

The claims of the patent cover methods of using biOasis’ brain penetrating drug delivery vector, Transcend, coupled with a lysosomal storage disease enzyme for the treatment of lysosomal

In addition, beginning 24 months after execution of the agreement, CryoLife has the right to acquire the ProCol product line from Hancock Jaffe. Key aspects of transaction: –

iBio intellectual property vice president Dr Wayne P. Fitzmaurice noted that the antibodies covered by these patents are designed to block critical functions of the influenza virus necessary

Pursuant to the terms of the agreement, PACK Pharmaceuticals will receive $80m in cash and $5m in ACETO stock. In addition, the agreement provides for a three-year earn-out

The acquisition brings two products to Retrophin that have been approved by the US Food and Drug Administration (FDA). Chenodal (chenodeoxycholic acid — a synthetic bile acid also

AllStar president Dr. Bagi noted that the company is extremely pleased to be able to work with BIOVEA, as they are an established successful online sales organization, and

Discovered by Takeda, TAK-438 belongs to a new class of acid secretion inhibitors called potassium-competitive acid blockers (P-CAB). In February 2014, a new drug application (NDA) for TAK-438